
WSW, NY, November 17th, 2026, FinanceWire Lifeward’s AlterG rehabilitation business alone generated $12.9 million in 2025 revenue and has posted double-digit growth in each of the last two quarters, yet
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| BWAY | Brainsway | 8.48 | 1.03 | 13.90% |
| Name | Price | % Change | |
|---|---|---|---|
| $8.48 | +13.90% |

WSW, NY, November 17th, 2026, FinanceWire Lifeward’s AlterG rehabilitation business alone generated $12.9 million in 2025 revenue and has posted double-digit growth in each of the last two quarters, yet

Brainsway (($BWAY)) has held its Q3 earnings call. Read on for the main highlights of the call. BrainsWay Earnings Call Highlights Strong Growth and Profitability The earnings call struck a

The latest announcement is out from Brainsway ( ($BWAY) ). On November 10, 2026, BrainsWay filed a report furnishing its November investor deck. The company reported third-quarter revenue of $18.1

Reports Q3 revenue $18.15M, consensus $17.8M. “Our third-quarter results demonstrate our ability to translate strong revenue growth into higher profitability and cash generation. Revenue increased 34%, while operating income grew

The company said, “Based on strong performance and increased visibility into the remainder of the year, BrainsWay (BWAY) now expects full-year 2026 results to be at the upper end of

Brainsway ( ($BWAY) ) has issued an update. BrainsWay Ltd. is a global neurotechnology company focused on noninvasive neurostimulation treatments for mental health disorders. Its proprietary Deep TMS platform has

Brainsway (BWAY) is scheduled to report 3rd quarter earnings on 11/10/2026, before the market opens. Regarding Q3 estimates, Wall Street analysts expect Brainsway to post earnings of $0.09 per share.

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Brainsway, retaining the price target of $19.00. Ram Selvaraju’s rating is based on BrainsWay’s new collaboration with Mindful Health

Brainsway ( ($BWAY) ) has shared an update. BrainsWay is a global medical technology company focused on noninvasive neurostimulation treatments for mental health disorders. Its primary products include the Deep

BrainsWay (BWAY) announced a strategic collaboration with Mindful Health Solutions, an established provider of comprehensive behavioral health and interventional psychiatry services. In August, Mindful Health Solutions’ managed services organization was
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 17, 2027TBA | $362.37M | $0.09 | $18.95M | 0.07 | 34.55 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.